Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, alleging the company misled investors about its Phase III Fianlimab-Libtayo study results. The complaint claims Regeneron made false positive statements while concealing that the trial was failing to meet key clinical endpoints. After disclosures in April and May 2026 about trial changes and failure to reach statistical significance, Regeneron's stock price dropped sharply. Investors who suffered losses can join the lawsuit before the September 14, 2026 deadline to seek compensation.
Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals for allegedly providing false and misleading information about its Phase III Fianlimab-Libtayo study. The complaint claims Regeneron concealed that the trial was...
In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...
